1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 15 SEPTEMBER 2014

CNS Drug News 15 SEPTEMBER 2014

  • September 2014
  • -
  • Espicom Business Intelligence
  • -
  • 16 pages

Industry Trend Analysis - FDA-Approved Contrave Enters Tough And Competitive Market
Industry Trend Analysis - Nuplazid's FDA Breakthrough Therapy Designation Boosts ACADIA
Industry Brief - Phase IIa Study Of NeuroDerm's Liquid Levodopa/Carbidopa For PD Commences
Industry Brief - Avanir Reports Positive AVP-923 Phase II Results For Agitation In AD Patients
Industry Brief - GeNeuro Reports Positive Results From GNbAC1 Phase IIa Trial In MS
Industry Trend Analysis - Calico Collaboration To Further Expand AbbVie's Portfolio
Industry Brief - FDA Grants ODD To Prana's PBT2 For HD
Industry Brief - Evotec/CHDI Extend Collaboration
Industry Brief - KineMed Receives US Patent Allowance For Noscapine to Treat ALS/PD/DN
Industry Brief - OB Halts Oxycyte Phase IIb TBI Trial
Industry Brief - Meiji/Takeda Finalise Co-Promotion Agreement For Rozerem In Japan
Industry Brief - Teva Launches Escitalopram In Canada
Industry Brief - Lannett Gains US Oxycodone Approval
Industry Brief - First Patient Enrolled In MDX Phase IIb Trial In Adolescents With ADHD
Industry Brief - Mallinckrodt's MNK-155 Shows Efficacy In Phase III Acute Pain Trial
Industry Brief - Acura Submits Formal Dispute Resolution Request With FDA
Industry Brief - Court Overturns Dexmedetomidine Temporary Restraining Order
Industry Brief - Depomed Summary Judgment Motion Granted In Gralise Orphan Drug Exclusivity Suit
Industry Brief - New NIDA Grant Awarded For MN-166 In Opioid Dependence
Industry Brief - Eisai Sells US/Puerto Rican Zonegran Rights To Concordia
Industry Brief - Ligand Licenses Captisol-enabled Lamotrigine To CURx
Industry Brief - FDA Accepts Vyvanse sNDA For Filing With Priority Review
Industry Trend Analysis - Tesaro's Rolapitant On Course To Compete With Merck's Emend In 2015
Industry Brief - Opexa Commences OPX-212 Development Programme In NMO
Industry Brief - CNS Conferences - December 2014

Table Of Contents

CNS Drug News 15 SEPTEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.